Compare iShares Gold Trust (IAU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Twist Bioscience Corp — how do they compare? iShares Gold Trust trades at $78.79 (market cap $61.51B), while Twist Bioscience Corp trades at $161.08 (market cap $10.08B). The key difference: iShares Gold Trust is far larger — about 6.1× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Twist Bioscience Corp for 27 Days on average.
| IAU | TWST | |
|---|---|---|
Market Cap | $61.51B | $10.08B |
Volume | 3,206,729 | 4,229,037 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $205.00 |
52-Week Low | $74.21 | $25.45 |
Typical Hold Time | 49 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU is trading at $78.60, up 2.0% over the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $78-$79, with support at $76-$77. Recent news highlights sensitivity to interest rate expectations and Treasury yields, with gold's performance influencing sentiment. Financial ratios are currently unavailable for analysis.
The outlook remains cautious due to bearish technicals and macroeconomic pressures from rising yields. Investment opportunities may arise if the stock holds key support levels amid potential Fed policy shifts, but risks include further downside if rate-hike fears persist or economic data weakens gold's appeal.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
